Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
SALT LAKE CITY—A recent filing with the Securities and Exchange Commission reveals that Austin Aerts, Chief Financial Officer of Sera Prognostics , Inc. (NASDAQ:SERA), a $146 million market cap company currently trading at $4.32, executed a sale of company shares. According to InvestingPro data, the company maintains a strong liquidity position with more cash than debt on its balance sheet. On March 6, Aerts sold 540 shares of Class A Common Stock at a weighted average price of $4.16 per share, totaling approximately $2,246. This transaction was conducted to cover tax withholding obligations related to the vesting of restricted stock units, as mandated by the company’s policies, rather than being a discretionary sale. The transaction comes as the stock has experienced a significant decline, down nearly 55% over the past year. Get access to 8 more key insights about SERA with an InvestingPro subscription, including detailed Fair Value analysis and comprehensive financial health metrics.
In addition to the sale, Aerts acquired 37,650 shares of Class A Common Stock on March 5, as part of a restricted stock unit grant, and 53,810 stock options with a right to buy, both at no cost. These acquisitions are part of a structured vesting schedule, contingent upon Aerts’ continued service with the company. Following these transactions, Aerts holds 314,520 shares directly in the company, which currently maintains a current ratio of 2.11, indicating strong short-term liquidity.
In other recent news, Sera Prognostics has made several significant announcements. The company has terminated its "at-the-market" (ATM) offering prospectus, which aimed to sell up to $50 million of its Class A common stock. This decision was confirmed through a recent SEC filing, although the company has not disclosed specific reasons for halting the offering. In a separate development, Sera Prognostics has launched a new public offering of Class A common stock and pre-funded warrants. Managed by Jefferies, TD Cowen, William Blair, and RBC Capital Markets, the proceeds from this offering are intended to expand U.S. operations and support EU growth, among other purposes.
Additionally, Sera Prognostics has revealed that the Society for Maternal Fetal Medicine has published an abstract with topline results from the PRIME study, focusing on improving neonatal outcomes. These results will be discussed in detail at the SMFM 2025 Pregnancy Meeting later this month. Following this presentation, Sera Prognostics plans to host a conference call and live audio webcast to delve deeper into the study’s findings. Investors are keeping a close watch on these developments, as they reflect the company’s ongoing efforts to enhance its market presence and advance its research initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.